Will Decentralized Clinical Trials Compound Patient and Data Quality Risks?
Recent research has emboldened the industry as it moves from traditional to hybrid studies with the promise of greater patient participation and patient access – despite this risk to overall study quality data was cited as the number one concern with decentralized trials. How can these risks be mitigated against? Live: Tuesday, Oct. 29, 2019 at 1pm EDT | 12pm CDT | 10am PDT On demand available after airing until Oct. 29, 2020. Register free
Decentralized Clinical Trials (DCTs) offer a more patient-centric approach in which fewer clinic visits are required and patient and caregiver burden are reduced. DCTs utilize a wide range of digital technologies to collect safety and efficacy data from study participants, normally remotely from the patient’s own home.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- The Impact of ICH E6(R3) on Biospecimen Management
June 25th 2025
- The Top 5 Myths About eCOAs In 2025
March 25th 2025